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ABSTRACT: Poly(ethylene glycol) (PEG) conjugates of Dicer-substrate
small interfering RNA (DsiRNA) have been prepared to investigate a new
siRNA release strategy. 3′-sense or 5′-antisense thiol-modified, blunt-ended
DsiRNAs, inhibiting enhanced green fluorescent protein (eGFP)
expression, were covalently conjugated to PEG with varying molecular
weights (2, 10, and 20 kg/mol) through a stable thioether bond using a Michael addition reaction. The DsiRNA conjugates with
2 kg/mol PEG (both 3′-sense or 5′-antisense strand conjugated) and the 10 kg/mol PEG conjugated to the 3′-sense strand of
DsiRNA were efficiently cleaved by recombinant human Dicer to 21-mer siRNA, as determined by gel electrophoresis.
Importantly, 2 and 10 kg/mol PEG conjugated to the 3′-sense strand of DsiRNA showed potent gene silencing activity in human
neuroblastoma (SH-EP) cells, stably expressing eGFP, at both the mRNA and protein levels. Moreover, the 10 kg/mol PEG
conjugates of the 3′-sense strand of DsiRNA were less immunogenic when compared with the unmodified DsiRNA, determined
via an immune stimulation assay on human peripheral blood mononuclear cells.
■ INTRODUCTION
RNA interference (RNAi)1−4 provides a promising platform for
treatment of gene-related diseases including cancer and viral
infections. Among several triggers of RNAi, 21−23-nucleotide-
long, 3′-overhanging, small interfering RNAs (siRNAs) have
been widely utilized as one of the best established RNAi
mediators.3−6 In recent years, dicer-substrate small interfering
RNAs (DsiRNAs), 25−30 nucleotide-long RNA designs, have
proved to have improved potency over conventional siRNAs in
triggering RNAi in mammalian cells.7−16 DsiRNAs are cleaved
by Dicer enzyme in the cytoplasm of cells into 21- to 23-
nucleotide-long siRNA. It has been suggested that the
involvement of Dicer enzyme in the formation of siRNA
plays an important role in the formation of RNA-induced
silencing complex (RISC) and consequently leads to highly
efficient gene silencing.7 However, the therapeutic potency of
both siRNA and DsiRNA is limited by their pharmacokinetic
problems such as nonspecific distribution, rapid clearance, and
immunogenicity.10,14−17 The use of DsiRNA increases the
possibility of interferon (IFN) induction,18,19 although the IFN
response to DsiRNA varies significantly among different cell
types.20 DsiRNA has improved nuclease-stability compared
with siRNA.14 Both structures have a short in vivo half
life.10,17,21
Poly(ethylene glycol) (PEG) is a well-known, nonimmuno-
genic, long-circulating polymer. Covalent conjugation of PEG
(“PEGylation”) has been shown to improve the in vivo
pharmacokinetics of protein drugs by reducing immunogenicity
and preventing rapid clearance.22−28 PEGylation has also been
investigated for siRNA delivery in a number of studies and
shown to improve the therapeutic efficacy.17,29−38 To trigger
the RNAi mechanism by siRNA-PEG conjugates, PEG needs to
be conjugated to siRNA via covalent bonds cleavable by a
physiological stimulus. The most widely used bonds for
reversible siRNA-PEG conjugates include disulfide
bonds31,37,38 cleavable by reduced glutathione inside the
cytoplasm and acid-labile bonds34 cleavable at endosomal/
lysosomal pH. Using such reversible bonds enables the release
of siRNA from the polymer chain inside the cell.
In our present study, PEG conjugates of DsiRNA have been
investigated for the first time as a new siRNA delivery strategy
using polymeric carriers. PEG was conjugated to DsiRNA via a
physiologically stable covalent bond. It was hypothesized that
the release of siRNA from the PEG chain would occur in the
cytoplasm via Dicer enzyme activity and the released siRNA
would lead to efficient gene silencing. To investigate this novel
strategy, 3′-sense or 5′-antisense thiol-modified, we covalently
conjugated blunt-ended DsiRNAs, targeting against enhanced
green fluorescent protein (eGFP) expression were covalently
conjugated to PEG with varying molecular weights via a stable
thioether bond using a mild and efficient synthetic approach
(via Michael addition reaction).39 The release of siRNA from
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the DsiRNA-PEG conjugates was investigated in vitro using
recombinant human Dicer. The gene silencing efficiency of the
conjugates was investigated using in vitro cultured human
neuroblastoma SH-EP cells stably expressing eGFP and
immunogenic properties in human peripheral mononuclear
cells (PBMCs). The results have been presented below.
■ MATERIALS AND METHODS
Materials. Monomethoxy poly(ethylene glycol) (mPEG, 2 and 5
kg/mol), PEG (10 and 20 kg/mol), acryloyl chloride, acetyl chloride,
and dithiothreitol (DTT) were purchased from Sigma-Aldrich.
Triethylamine (TEA), dichloromethane, ethyl acetate, and acetonitrile
were supplied from Ajax Finechem. mPEG of 10 and 20 kg/mol were
synthesized via an acylation reaction of one of the hydroxyl end-group
with acetyl chloride.
All 27-nucleotide-long, blunt-ended, nonmodified, double-stranded
RNA oligonucleotides (DsiRNA) used in this study were previously
reported by Kim et al. and are known to silence eGFP expression.7
The DsiRNA sequences used in the study are summarized in Table S1,
Supporting Information (SI). They were synthesized and standard
desalting-purified by Integrated DNA Technologies (IDT). The
DsiRNAs were solubilized in HEPES (4-(2-hydroxyl)piperazine-1-
ethanesulfonic acid) buffer (pH 7.5) (IDT) to 500 μM concentration
following manufacturer’s resuspension protocol. RNase free water was
also purchased from IDT. Conventional 21-nucleotide siRNAs (Table
S1, SI) were purchased from IDT or Qiagen.
Active fetal bovine serum (FBS) (sourced from Australia) and
human serum (HS) utilized in stability experiments were purchased
from JRH-Biosciences and Lonza, respectively. Human neuroblastoma
SH-EP cells stably expressing eGFP (Children’s Cancer Institute of
Australia, Sydney)40 were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen), supplemented with 10% heat
inactivated FBS (SAFC Biosciences). Cell culture flasks and plates
were purchased from NUNC. Hank’s balanced salt solution (HBSS)
was purchased from SAFC Biosciences. Trypsin-EDTA was purchased
from Thermo Scientific. Lipofectamine-2000 was purchased from
Invitrogen. CellTiter-Blue cell viability assay reagents were purchased
from Promega.
In addition to Tris/borate/EDTA (TBE) loading and running
buffers (Biorad), 3% agarose or 15% polyacrylamide TBE-urea gels
(Biorad) were used in gel electrophoresis experiments. GelRed
(Biotium) was used for staining.
Recombinant human dicer and the enzymatic reaction reagents
were purchased from Genlantis.
Power SYBR green PCR master mix used in PCR experiments was
purchased from Applied Biosystems. β2-microglobulin Quantitect
primer assay was purchased from Qiagen. RIPA lysis buffer (50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium
deoxycholate, 0.1% SDS) containing protease inhibitors used in
Western Blot experiments was purchased from Sigma. BCA protein
assay kit and Rabbit polyclonal antibody against eGFP were purchased
from Pierce and Cell Signaling Technology, respectively. RPMI
supplemented with 2 mM L-glutamine used in immune stimulation
assay was purchased from Invitrogen. Quantitect reverse transcription
kit and the IFIT-1 quantitect primer assay were purchased from
Qiagen. CellTiter-Blue cell viability assay was purchased from
Promega.
All other reagents were analytical grade and used as received.
Methods. Synthesis of PEG-acrylate (Mn = 2 and 5 kg/mol)
(Scheme S1, Supporting Information). In a 250 mL round-bottomed
flask, mPEG (2 mmol) was dissolved in dichloromethane (CH2Cl2)
(50 mL) and dried using a rotary evaporator. CH2Cl2 (50 mL) was
then introduced and the solution was cooled in an ice bath. A mixture
of acryloyl chloride (3 mmol) and TEA (3.3 mmol) was added
dropwise. After 1 h, the resulting solution was warmed to room
temperature and stirred overnight. The product was purified by
dialysis and analyzed by 1H NMR and aqueous GPC. 1H NMR (300
MHz, CDCl3, δ): 3.37 (s, 3H, −O−CH3), 3.64 (t, n × 4H,
−O(CH2CH2)nO−), 4.30 (t, 2H, −CO2−CH2−), 5.82 (dd, 1H,
CH2CH−), 6.15 (q, 1H, CH2CH−), 6.41 (dd, 1H, CH2
CH−). 1H NMR spectra were recorded on a Bruker ACF300 (300
MHz) spectrometer. The end-group functionality of both PEG Mn,GPC
= 2 (PDI = 1.03) and Mn,GPC = 5 (PDI = 1.05) was found to be close
to 100%. Figure S1 in SI shows the NMR spectrum of PEG-acrylate
(Mn = 5 kg/mol).
Synthesis of PEG-acrylate (Mn = 10 and 20 kg/mol). mPEG was
first synthesized via an acylation reaction of one of the hydroxyl end
groups of PEG (Mn 10 and 20 kg/mol) with acetyl chloride. A typical
procedure is given for PEG (Mn 10 kg/mol): In a 100 mL round-
bottomed flask, mPEG (2 g, 0.2 mmol) was dissolved in dichloro-
methane (CH2Cl2) (50 mL) and dried by azeotropic distillation to
remove trace of water. CH2Cl2 (50 mL) was introduced, and the
solution was cooled in an ice bath. A mixture of acryloyl chloride (0.22
mmol) and TEA (0.5 mmol) was added dropwise. After 1 h, the
resulting solution was warmed to room temperature and stirred
overnight. A solution of acryloyl chloride (0.3 mmol) was added
dropwise. The product was purified by dialysis and analyzed using a
Bruker ACF300 (300 MHz) spectrometer and by GPC. 1H NMR
(300 MHz, CDCl3, δ): 3.00 (s, 3H, −O−(CO)CH3), 3.64 (t, n × 4H,
−O(CH2CH2)nO−), 4.10 (s, 3H, CH2−O−(CO)CH3), 4.30 (t, 2H,
−CO2−CH2−), 5.82 (dd, 1H, CH2CH−), 6.15 (q, 4H, CH2
CH−), 6.41 (dd, 1H, CH2CH−). The end-group functionality was
calculated by the ratio of intensity of signal at 4.30 and 4.20 and found
to be 85 and 75% in the case of PEG Mn,aqueousGPC 10 kg/mol (PDI =
1.04) and 20 kg/mol (PDI = 1.02), respectively.
DsiRNA Conjugation with PEG-Acrylate. A solution of TEA (14
nmol, 0.14 × 10−3 M), DTT (5 μmol, 50 × 10−3 M), and 3′-sense or
5′-antisense thiol-modified DsiRNA (12 nmol, 0.12 × 10−3 M) in
RNase-free water (100 μL) was mixed for 15 min. DTT was removed
by extractions with equal volumes of saturated ethyl acetate. The
aqueous phase collected from extractions was mixed with a solution of
PEG-acrylate (600 nmol, 6 × 10−3 M) in phosphate buffer (0.1 M, pH
8, 100 μL) and shaken overnight at 37 °C. The formation of
conjugates was verified by agarose gel electrophoresis using Bio-Rad
Ready Precast Gel System (Bio-Rad). The conjugation reaction
mixtures and DsiRNAs were run on a precast 3% ethidium bromide-
agarose gel at 100 V for 45 min using tris/borate/EDTA (TBE)
loading and running buffers. Gels were visualized by Gene Genius Bio
Imaging System (Syngene), then quantified using Image J software
(National Institutes of Health, U.S.). The conjugates prepared in this
study were coded as given in Table 1.
Gel permeation chromatography (GPC) was also used to verify the
conjugation of DsiRNAs with different PEGs. GPC was performed
using Shimadzu modular system comprising a DGU-12A solvent
degasser, on LC-10AT pump, a CTO-10A column oven, and a RID-
10A refractive index detector and a SPD-10A Shimadzu UV−vis
detector (flow rate: 1 mL/min). The column system was equipped
with a Polymer Laboratories 5.0 mm bead-size guard column (50 × 7.8
mm2), followed by two PL aquagel MIXED−OH columns (8 μm).
Calibration was performed with PEO standards ranging from 0.106 to
909.5 kg/mol.
Conjugates were purified by high-performance liquid chromatog-
raphy (HPLC) using a C18 column (300 × 3.9 mm2, 10 μm,
Phenomenex) equipped with a UV detector at 220 and 260 nm. Liquid
chromatography was carried out under the following conditions:
mobile phase A, 0.025 M phosphate buffer (pH 7); mobile phase B,
acetonitrile; a gradient elution from 1 to 50% B in 30 min and then
maintained at 50% B for 10 min; and flow rate 1.0 mL·min−1, column
temperature: 25 °C. Subsequently conjugates were dialyzed for 2 days
Table 1. Codes of the Synthesized Conjugates
thiol modification site of DsiRNA
duplex
conjugated PEG number-average
molecular weight (kg/mol)
2 5 10 20
3′-sense strand 3′-2k 3′-5k 3′-10k 3′-20k
5′-antisense strand 5′-2k 5′-5k 5′-10k 5′-20k
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against water using a dialysis membrane (Spectrum, USA) with
molecular weight cutoff (MWCO)-10 kg/mol for 2 and 5 kg/mol
conjugates and MWCO-25 kg/mol for 10 and 20 kg/mol conjugates.
Finally, all synthesized conjugates were freeze-dried and stored at −20
°C. The concentration of the conjugates was determined by UV-
spectroscopy at 260 nm using a double-beam Hitachi UV spectrometer
(model no. U2800).
In addition, DsiRNA was also conjugated with hydroxyethyl acrylate
(1 ethylene glycol unit) via the same method to compare more
accurately the impact of the end-group modification. This conjugate
was also purified in the same manner with the PEG conjugates.
Stability of Thioether Bond in DsiRNA-PEG Conjugates under
Acidic Conditions. DsiRNA-PEG conjugate (2 nmol, Mn (PEG) = 5
kg/mol) was dissolved in acetic acid buffer (200 μL, at pH 4.5 or 5.5).
The solution was shaken at 37 °C. At predetermined time points, an
aliquot was taken from this solution and frozen at −18 °C. The
stability of the bond between RNA and the polymer was analyzed by
gel electrophoresis using 3% agarose or PAGE TBE urea gels.
In Vitro Human Dicer Activity by Recombinant Human Dicer.
The human Dicer activity on the conjugates was tested following a
protocol suggested by the supplier and also used by other groups.7 In
brief, DsiRNA (50 pmol) was incubated with 1 or 2 units of
recombinant human dicer at 37 °C for 24 and 48 h. The reaction was
performed in Dicer reaction buffer (10 μL, containing 24 mM HEPES,
200 mM NaCl, 40 μM EDTA, 1 mM ATP, 2.5 mM Mg2Cl, pH 8 for
reaction with 1 unit of Dicer). All cofactors were proportionally scaled
up when 2 units of Dicer were used; only the amount of reacted
DsiRNA remained the same (50 pmol). At the end of incubation time,
the Dicer activity was quenched by the addition of stop solution (2 μL,
10 mM EDTA). The samples (1 μL) were analyzed on a Small RNA
Lab-on-a-Chip (Agilent Technologies) using an Agilent 2100
Bioanalyzer (Agilent Technologies).
The same Dicer reaction conditions were applied to the conjugates.
The conjugate samples were analyzed via PAGE using a 15%
polyacrylamide TBE-urea gel at 180 V for 50 min and visualized by
Gene Genius Bio imaging system. As a control marker, 21-mer siRNA
was also loaded onto the gel. All dicing experiments were performed at
least twice.
Cell Culture and Transfections. The human neuroblastoma cell
line (SH-EP) that stably expresses eGFP was maintained as a
monolayer in DMEM containing 10% FCS and 2 mM of L-glutamine.
The cells were grown at 37 °C in a humidified atmosphere with 5%
CO2. To transfect cells with the 3′-sense or 5′-antisense PEG
conjugated DsiRNAs (27-mer) targeting eGFP, we plated cells at
1.5 × 105 for 16 h before transfection. The following day cells were
transfected with the conjugates at differing concentrations ranging
from 0.5 to 10 nM using lipofectamine 2000 following the
manufacturer’s instructions. Cells transfected with conventional 21-
mer siRNA (100 nM) or unmodified 27-mer DsiRNA (0.2−10 nM)
against eGFP were used as a positive control. Total RNA and cell
lysates were collected 48−72 h post-treatment, and eGFP mRNA and
protein levels were assessed using real-time PCR and Western blotting.
Measurement of eGFP mRNA Levels by Real-Time PCR. The
expression of eGFP in SH-EP cells stably expressing eGFP was
examined using real-time quantitative PCR. In brief, total RNA was
collected and DNase-treated using the Qiagen RNeasy plus mini kit
according to the manufacturer’s instructions. Total RNA (0.5 μg) was
reverse-transcribed. Real-time PCR was performed using the Power
SYBR green PCR master mix according to the manufacturer’s
instructions using an Applied Biosystems 7500 real-time PCR system.
Scheme 1. Conjugation of PEG-Acrylate with Thiol-Modified DsiRNA via Michael Addition (n = 45, 110, 225, 450)
Figure 1. Agarose gel electrophoresis of 3′-sense thiol-modified-DsiRNA before and after conjugations. (A) Crude conjugate mixture. (B) HPLC-
purified conjugates: line 1: 3′-sense thiol-modified DsiRNA (before conjugation), line 2: DsiRNA-HEA conjugate, and lines 3−6: DsiRNA-PEG
conjugates (from 2 to 20 kg/mol PEG).
Biomacromolecules Article
dx.doi.org/10.1021/bm201199c | Biomacromolecules 2011, 12, 4301−43104303
The primers for eGFP were as described previously, eGFP forward 5′-
ATGGTGAGCAAGGGCGAGGA-3 ′ and eGFP reverse 5 ′-
ACTTGTGCCCGTTTACGTCGC-3′.41 All data were normalized
to the housekeeping gene β2-microglobulin (β2-microglobulin
Quantitect primer assay). All experiments were performed at least
three times.
Measurement of eGFP Protein Levels by Western Blotting. Cell
lysates were prepared from cells transfected with 3′-sense or 5′-
antisense PEG conjugated DsiRNAs targeting eGFP by resuspending
in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-
40, 0.25% sodium deoxycholate, 0.1% SDS) containing protease
inhibitors and incubated for 1 h on ice. Cell debris were cleared by
centrifuging the lysates for 10 min at 13 000g at 4 °C. Supernatants
were then collected and stored at −80 °C until analysis. Total protein
in the lysates was determined using the BCA protein assay kit
according to the manufacturer’s instructions. Equal protein amounts
(10 μg) were loaded onto 10% SDS PAGE gels and transferred to
nitrocellulose. eGFP protein expression was detected using a Rabbit
polyclonal antibody against eGFP according to the manufacturer’s
instructions. Enhanced chemiluminescence (GE Healthcare) was used
for detection. Densitometry was performed using ImageQuant
software version 5.2 (Molecular Dynamics). Equal protein loading
was confirmed by probing the membranes against the housekeeping
protein GAPDH. All experiments were performed at least three times.
Fluorescence Microscopy Investigation of eGFP Inhibition.
Round coverslips (13 mm) were first sterilized in 70% ethanol and
washed twice with PBS and DMEM, then placed in wells of a 24-well
microplate. SH-EP cells stably expressing eGFP were seeded at a
concentration of 2 × 104 cells/mL in 500 μL of media (DMEM with
10% FCS and 2 mM of L-glutamine) per well and incubated overnight
at 37 °C in a humidified atmosphere 5% CO2. Cells were then
transfected with nonmodified DsiRNAs or the PEG conjugated
DsiRNAs (10 pmol, 500 μL in DMEM with 10% FCS and 2 mM L-
glutamine) using lipofectamine 2000 following the manufacturer’s
instructions. The coverslips were loaded onto microscope slides 72 h
post-treatment and investigated using an Olympus Bx61 Fluorescent
Microscope (Olympus, US). Each treatment was tested in three
independent experiments. Cells (1 mL, 1 × 104 cells/mL) cultured
without any treatment were used as the positive control.
Immune Stimulation Assays. To examine whether PEG-modified
DsiRNAs were immunogenic, we obtained freshly collected blood
from healthy human donors (HREC-09226). Peripheral blood
mononuclear cells (PBMCs) were isolated using Ficoll-density
gradient centrifugation and plated in a six-well plate containing
RPMI supplemented with 10% FCS and 2 mM L-glutamine. For
immunostimulation, PBMCs were treated with unmodified 27-mer
DsiRNA (90nM) or 3′ 10K-PEG-modified DsiRNA (90nM). PBMCs
treated with 50 μg [poly(I:C)] were used as a positive control. Total
RNA was isolated using trizol as described previously 24 h post-
treatment.42,43 cDNA was reverse-transcribed, and DNase was treated
using the Quantitect reverse transcription kit according to the
manufactures instructions. Real-time PCR was performed as described
above to measure the IFN-inducible gene, IFN-induced protein with
tetratriocopeptide repeats (IFIT-1) using the IFIT-1 quantitect primer
assay. All data were normalized to the housekeeping gene β2-
microglobulin (β2-microglobulin Quantitect primer assay). All experi-
ments were performed using at least three separate PBMC isolations.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of PEG-Conjugated
Dicer Substrate siRNAs. 3′-Sense or 5′-antisense thiol-
modified, 27-mer, blunt-ended DsiRNAs were conjugated
with acrylate-modified PEG (PEG-acrylate) and hydroxyethy-
lacrylate (HEA) via thioether bond, which is known to be
physiologically stable.44 The conjugation between DsiRNAs
and PEG-acrylate was performed via a Michael addition
reaction39,45 of thiol group of DsiRNA to the acrylic bond of
PEG (Scheme 1). The conjugates prepared with PEGs having
varying molecular weights are listed in Table 1. The formation
of conjugates was first verified using gel electrophoresis. A
representative gel electrophoregram of the conjugation reaction
mixtures of 3′-sense DsiRNA and PEG-acrylates is shown in
Figure 1A. The shift of the DsiRNA band to higher molecular
weights according to the molecular weight of the conjugated
PEG was clear on the gels. The presence of unconjugated
DsiRNA was also observed on the gel electrophoregrams.
Integrating the intensity of the unconjugated DsiRNA bands
using Image J software, the percent conjugation yields
[(conjugated DsiRNA: total DsiRNA used in the reaction) ×
100] were determined to be between 56 and 76%. A small
amount of DsiRNA dimers (DsiRNA−S-S-DsiRNA structure)
was also observed on the gel. The formation of dimers to some
degree can be expected during the conjugation reaction after
the removal of DTT. Finally, gel electrophoregrams also
presented bands (in Figure 1A line 4) of secondary products
generated from the bis-hydroxylPEG impurities, attributed to
DsiRNA-PEG-DsiRNA conjugates. During the synthesis of
PEG-acrylate, both of PEG’s end-group hydroxyl groups may
be functionalized with an acrylate yielding bisfunctional PEG-
acrylate, which may result in the conjugation of two RNAs to
one PEG chain. The conjugation yields of 5′-antisense-modified
DsiRNA with PEG-acrylates, determined in the same manner,
showed also similar results to those of 3′-sense-modified
DsiRNA (data not shown). The conjugations were also verified
Figure 2. Bioanalyzer electroporation of 3′-sense- and 5′-antisense-thiol-modified DsiRNA (50 pmol) before and after incubation with 1 or 2 units of
recombinant human Dicer for 24 or 48 h. Green line represents the smallest marker added as internal standard used to align sample with the ladder
data. Lines: L, ladder; 1, blank; 2−5, 3′-sense-modified DsiRNA (2, before incubation with Dicer; 3, after incubation with 1 unit of Dicer for 24 h; 4,
after incubation with 2 units of Dicer for 24 h; 5, after incubation with 2 units of Dicer for 48 h); 6−9, 5′-antisense-modified DsiRNA (6, before
incubation with Dicer; 7, after incubation with 1 unit of Dicer for 24 h; 8, after incubation with 2 units of Dicer for 24 h; 9, after incubation with 2
units of Dicer for 48 h).
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by aqueous gel permeation chromatography (GPC) (Figure S2,
SI). Chromatograms of 3′-sense-modified DsiRNA and 5′-
antisense-modified DsiRNA clearly showed the shift of the
RNA signal to the lower retention times after the conjugation
according to the molecular weight of the PEG-acrylate attached.
The conjugates were then purified by HPLC, followed by
dialysis to remove the unconjugated DsiRNA and disulfide
dimers. Figure 1B shows the representative gel electrophore-
gram of the 3′-sense DsiRNA-PEG conjugates after the
purification process. It is clear from the gel that the free
DsiRNA and dimers were removed completely after the
purification.
The release of siRNA from the DsiRNA-PEG conjugate is
intended to be triggered only by the action of the Dicer
enzyme. Therefore, the bond between DsiRNA and PEG
should be stable until the conjugates meet the Dicer enzyme
inside the cytoplasm. It is known that the ester bond between
DsiRNA and PEG can hydrolyze at acidic pH values. To
investigate the stability of the conjugates at slightly low pH
similar than those found in intracellular acidic vesicles such as
endosomes and lysosome, the 5′-antisense-modified DsiRNA-
PEG conjugate (Mn PEG = 5 kg/mol) was incubated at two
different pH values (4.5 and 5.5) at 37 °C for 48 h. The
samples were then analyzed by gel electrophoresis to see the
presence of RNA released from the polymer. No free RNA was
detected, indicating that the thioether and ester bonds were
stable at acidic pH environment (Figure S3, SI).
It is well known that PEGylation improves the nuclease
resistance and serum stability of siRNA.31−33,35,38 DsiRNA
designs have higher nuclease resistance and serum stability
when compared with siRNA.7,14−16 An in vitro serum stability
assay that was performed by incubating nonmodified DsiRNA
or PEGylated DsiRNA in 90% FBS for up to 48 h showed that
PEGylated DsiRNA (either 3′-sense or 5′-antisense conjugates)
has serum stabilities similar to nonmodified DsiRNA. Both
PEGylated and nonmodified DsiRNA could keep its structural
integrity up to 12 h in 90% serum (Figure S4, SI).
Dicer Cleaves 21-mer siRNA from PEG-Conjugated
Dicer Substrate siRNAs. Ideally, conjugation of PEG should
not alter the conversion of DsiRNA by Dicer enzyme to 21-mer
siRNA. To test this hypothesis, we first examined Dicer
cleavage of the nonconjugated, 3′- and 5′-thiol-modified
DsiRNAs in vitro using Bioanalyzer, a microfluidic-based
instrument providing electrophoretic separation on microchips
instead of gels. The results are shown in Figure 2. The
complete cleavage of 3′-sense thiol-modified DsiRNA to 21-mer
RNA was attained when 50 pmol DsiRNA was incubated with 2
units of Dicer enzyme for 48 h (Lane 5, Figure 2). The
complete cleavage of 5′-antisense thiol modified DsiRNA (50
pmol) by 2 units of Dicer occurred in 24 h; however, the data
revealed that the cleavage of 5′-antisense-thiol-modified
DsiRNA yielded 19-mer instead of 21-mer siRNA (Lane 9,
Figure 2).
Considering this finding, the DsiRNA-PEG conjugates (50
pmol) were incubated with 2 units of Dicer for 48 h and
analyzed by gel electrophoresis to investigate the cleavability of
the conjugates to 21-mer siRNA (Figure 3). The products
cleaved from the conjugates were compared with the
unmodified 27-mer DsiRNA and unmodified 21-mer siRNA.
All conjugates except 5′-10k, 5′-20k, and 3'-20k conjugates
showed some degree of cleavage by Dicer. It was observed from
the band intensities in Figure 3A,B that the 2k conjugates (both
3′-2k and 5′-2k conjugates) and 3′-10k conjugate were relatively
well-cleaved, leading to the formation of an RNA band at the
same level as the 21-mer siRNA band. Cleavage of 3′-20k did
not produce 21-mer RNA (Figure 3 B). Similarly, 5′-10k and 5′-
20k conjugates yielded an insignificant quantity of RNA traces
shorter than 27-mer(Figure 3C). It should be noted that a small
amount of free (unconjugated) 27-mer DsiRNA (5′- or 3′-thiol
modified) in all conjugate samples was present as nonpurified
samples was deliberately used to utilize the free DsiRNA in
each sample as an internal control. Hence especially for 5′-10k
and 5′-20k conjugates, the formation of the shorter RNA
sequences after the incubation with Dicer was attributed to the
cleavage of the free (unconjugated) 27-mer DsiRNAs by the
enzyme. In 3′-20k and 5′-20k conjugate samples, the increased
intensity of the 27-mer RNA bands after the incubation of the
conjugates with Dicer indicated that the Dicer activity yielded
mostly 27-mer DsiRNA or more probably RNA oligomer−PEG
conjugates that contain RNA segment shorter than 27-mer. No
Figure 3. Dicer activity on PEG-conjugated DsiRNAs. (A) 5′-antisense
DsiRNA-PEG (2 kg/mol) and 3′-sense DsiRNA-PEG (2 kg/mol)
conjugates, (B) 3′-sense DsiRNA-PEG (10 and 20 kg/mol)
conjugates, and (C) 5′-antisense DsiRNA-PEG (10 and 20 kg/mol)
conjugates before and after incubation with Dicer. (−) represents
untreated samples; (+) represents samples after incubation with 2
units of Dicer for 48 h. 27 and 21 represent unmodified 27-mer
DsiRNA and 21-mer siRNA, respectively, as controls. Each sample
contains 50 pmol RNA. Gel running conditions: 15% PAGE TBE urea
gel at 180 V for 50 min.
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attempt was made to analyze these products because the Dicer-
triggered release of 21-mer siRNA from the conjugates was the
primary interest in this study.
In conclusion, in this study, it was hypothesized that the
Dicer activity on the conjugates would generate the 21-mer
siRNA species. This hypothesis was generally supported by the
results obtained. In particular, 3′-2k and 3′-10k could be cleaved
clearly to 21-mer after reaction with dicer. Cleavage profile and
efficiency were affected by the conjugation site and the
molecular weight of PEG conjugated to the DsiRNA.
Consistent with the cleavage of unconjugated 5′-antisense
thiol-modified DsiRNA, which produced 19-mer instead of 21-
mer, cleavage of 5′-10k and 5′-20k conjugates by Dicer was less
site specific and perhaps random in the presence of conjugated
polymer when compared with the cleavage of 3′-sense-modified
DsiRNA and its conjugates. The differences in the Dicer
cleavability between the 3′-modified and 5′-modified DsiRNAs
and conjugates may be a result of the strand selection process
and binding of DsiRNA to the dicer enzyme. Indeed, 3′-
overhanging DsiRNA designs instead of blunt-ended DsiRNA
are more predictable and have a limited dicing pattern most
probably because of the defined 3′-PAZ binding site.8 3′-20k
conjugates could have been site-specifically cleaved by Dicer,
but it is probable that the larger size of the conjugated polymer
have sterically prevented the interaction of Dicer with DsiRNA.
As a control experiment, Dicer activity on a mixture of
(unconjugated) PEG and (unconjugated) DsiRNA was also
tested under the same conditions to examine if the presence of
PEG affected the Dicer enzyme activity. A mixture of
unconjugated 3′-sense or 5′-antisense-modified DsiRNA and
free PEG having varying molecular weights (at 1:1 mol ratio)
were incubated with Dicer enzyme. The mixtures were then
analyzed by gel electrophoresis (Figure S5, SI). The results
indicated that presence of PEG (regardless of its molecular
weight) did not inhibit the dicing activity of the enzyme
because the Dicer enzyme exhibited similar cleavage efficiency
with DsiRNA/polymer mixtures as it did with the unconjugated
DsiRNA samples without added PEG.
PEG-Conjugated Dicer Substrate siRNAs Efficiently
Silence eGFP. Human neuroblastoma (SH-EP) cells stably
expressing eGFP were transfected with the 3′-sense- or 5-
antisense-modified DsiRNA and their (HPLC-purified) con-
jugates with different sizes of PEG (2, 10, and 20 kg/mol) using
lipofectamine 2000 as a well-established transfection agent.
Cells treated with different sizes of PEG conjugated to the 3′-
sense strand of DsiRNA showed potent gene silencing activity
at both the mRNA and protein levels (Figure 4). Moreover, the
3′-2k and 3′-10k conjugates (3′-sense strand DsiRNA
conjugates with 2 kg/mol and 10 kg/mol PEG) displayed
similar patterns of gene silencing (Figure 4). For example, cells
Figure 4. Efficacy of 3′-sense PEG conjugated DsiRNAs targeting eGFP. Representative graphs showing eGFP mRNA levels in SH-EP cells stably
expressing eGFP treated with increasing concentrations (0.5−10 nM) of 3′-sense PEG (A) 2 kg/mol and (B) 10 kg/mol conjugated DsiRNAs
targeting eGFP. Data was expressed as a percentage of control. All data were normalized to the housekeeping gene β2-microglobulin. (n = 3 to 4
separate experiments, ***p < 0.0001). (C,D) Representative Western blots and densitometry demonstrating the effect of increasing concentrations
(0.5−10 nM) of 3′-sense PEG 2 or 10 kg/mol conjugated DsiRNA in silencing eGFP protein expression. GAPDH was used as loading control. All
data were normalized to the housekeeping protein GAPDH (n = 3 to 4 separate experiments, *p < 0.05, **p < 0.01, ***p < 0.0001).
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treated with 10 nM of the 3′-2k and 3′-10k conjugates were able
to silence eGFP mRNA levels by 74 ± 2% and 71 ± 5%,
respectively, when compared with control cells. Importantly,
the activity of the PEG-modified DsiRNA was not too
dissimilar to cells treated with unmodified 21-mer siRNA (50
nM) or 27-mer (1 nM) DsiRNA (Figure S6, SI). The reduced
gene silencing activity of PEG-modified DsiRNA with respect
to the unmodified 27-mer DsiRNA was attributed to the
incomplete cleavage of PEG-conjugated DsiRNA by dicer to
21-mer siRNA sequence silencing eGFP gene, in accord with
the results presented in Figure 3. Cells incubated with DsiRNA-
conjugated with the 20 kg/mol PEG on the 3′-sense strand
showed reduced gene silencing activity when compared with
the 2 and 10 kg/mol PEG dicer conjugates [gene silencing
activity, 3′-20k (10 nM) = 34 ± 2%; and 5-20k (10 nM) = 48 ±
3%] (Figure S7, SI). The decrease in gene silencing activity for
the 20 kg/mol PEG-modified DsiRNAs when compared with
the activity of 2 and 10 kg/mol PEG conjugates may be due to
the larger hydrodynamic volume of PEG, thus partially
inhibiting the ability of the dicer enzyme to interact with
modified DsiRNA.
To characterize fully the effect of PEG conjugated to
DsiRNA, we also examined different sizes of PEG (2, 10, and
20 kg/mol) conjugated to the 5′-antisense strand of the
DsiRNA. Cells treated with the 5′-antisense PEG conjugates
displayed reduced activity when compared with the 3′-sense
modified DsiRNA, with a maximum gene silencing of 58 ± 3%
for the 2 kg/mol conjugated PEG (10 nM) and 55 ± 3% for
the 10 kg/mol conjugated PEG conjugated DsiRNA (10 nM)
(Figure 5). The reduced gene silencing activity of 5′-antisense
conjugates when compared with the 3′-sense conjugates was
attributed to the poor cleavability of these conjugates by Dicer
to 21-mer siRNAs. There was a difference in the amount of
eGFP knockdown between the 5′-20k and 3′-20k conjugates
(Figure S7, SI). However, this decrease was very small with a %
knockdown difference between the two conjugates ranging
from 5.4 to 11.7% over the different concentrations of DsiRNA.
Moreover, the difference at the mRNA expression between the
two conjugates did not correlate at the protein level. Taken
together, the results demonstrate that different sizes of PEG are
able to be conjugated to DsiRNA with approximately 10-fold
inhibition in its gene silencing activity.
Gene silencing activity of the 3′-sense- or 5-antisense-
modified DsiRNA and their conjugates with different sizes of
PEG (2, 10, and 20 kg/mol) was also visualized via
fluorescence microscopy (Figures 6 and 7). Both the
nonmodified DsiRNA (10 nM) and 3′- and 5′-thiol-modified
DsiRNAs (10 nM) caused significant reduction in fluorescence
of SH-EP cells stably expressing eGFP. Transfection with 3′-
thiol-modified DsiRNA was the most efficient in silencing
eGFP expression. No significant difference in the silencing
effect of the unmodified DsiRNA and 5′-thiol modified
Figure 5. Efficacy of 5′-antisense PEG conjugated DsiRNAs targeting eGFP. Representative graph showing eGFP mRNA levels in SH-EP cells stably
expressing eGFP treated with increasing concentrations (0.5−10 nM) of 5′-antisense PEG (A) 2 kg/mol and (B) 10 kg/mol conjugated DsiRNAs
targeting eGFP. Data were expressed as a percentage of control. All data were normalized to the housekeeping gene β2-microglobulin. (n = 3 to 4
separate experiments, **p < 0.01 and ***p < 0.0001). (C,D) Representative Western blots and densitometry demonstrating the effect of increasing
concentrations (0.5−10 nM) of 5′-antisense PEG 2 or 10 kg/mol conjugated DsiRNA in silencing eGFP protein expression. GAPDH was used as
loading control. All data were normalized to the housekeeping protein GAPDH (n = 3 to 4 separate experiments, *p < 0.05, **p < 0.01, ***p <
0.0001).
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DsiRNA was observed. The DsiRNA-PEG conjugates (10 nM)
showed slightly less activity compared with the unmodified
DsiRNA and 3′- and 5′-thiol-modified DsiRNAs; nevertheless,
they significantly reduced the fluorescence of SH-EP cells
(Figures 6 and 7). The fluorescent microscope results were in
accord with the mRNA reduction and protein inhibition results
(Figures 4 and 5). The increase in the molecular weight of PEG
conjugated to DsiRNAs resulted in less efficient fluorescence
reduction. The 2 kg/mol conjugates (both 3′-2 and 5′-2 kg/
mol) were the most efficient at reducing the fluorescence of
SH-EP cells, followed by 10 and 20 kg/mol conjugates. Here it
should be noted that the cytotoxicity of the 3′-sense conjugates
with varying molecular weights do not significantly differ from
each other and the 3′-sense thiol-modified DsiRNA (Figure S8,
SI). Similar to the thiol-modified DsiRNAs, PEG conjugation
to the 3′-sense-strand of DsiRNAs displayed better fluorescent
reduction effect when compared with the PEG conjugation at
the 5′-antisense-strand.
PEG-Conjugated Dicer Substrate siRNAs Are Less
Immunostimulatory Compared with Unmodified Dicer
Substrate siRNAs. To examine whether conjugating PEG to
DsiRNA could affect the immunogenic potential of DsiRNA,
we treated human PBMCs with unmodified 27-mer DsiRNA or
its conjugate with 10 kg/mol PEG. Data obtained from the in
vitro dicer cleavage assay and gene silencing experiments
showed that there was very little difference between both the 3′-
2k and 3′-10k conjugates. This indicates that the transfection
efficiencies of both conjugates were very similar. As a proof-of-
principle, we wanted to determine whether PEG conjugated to
Figure 6. Representative phase contrast and fluorescence microscope
images of SH-EP cells stably expressing eGFP before and after
transfection with 3′-sense-thiol-modified DsiRNA and DsiRNA-PEG
conjugates. (A) Untreated cells; (B) cells treated with 10 nM of
nonmodified 27-mer DsiRNA; (C) cells treated with 3′-sense-thiol-
modified DsiRNA (10nM); (D) cells treated with 3′-sense-thiol-
modified DsiRNA conjugates of 2 kg/mol PEG(10nM); (E) cells
treated with 3′-sense-thiol-modified DsiRNA conjugates of 10 kg/mol
PEG (10nM); and (F) cells treated with 3′-sense-thiol-modified
DsiRNA conjugates of 20 kg/mol PEG (10nM). Cells (1 × 104 cells/
mL) were transfected with a final concentration of 10nM in 1 mL of
total well volume. Results shown are the representative images, n = 9.
Figure 7. Representative phase contrast and fluorescence microscope
images of SH-EP cells stably expressing eGFP before and after
transfection with 5′-antisense-thiol-modified DsiRNA and DsiRNA-
PEG conjugates. (A) Untreated cells; (B) cells treated with 10nM of
nonmodified 27-mer DsiRNA; (C) cells treated with 5′-antisense-thiol-
modified DsiRNA (10nM); (D) cells treated with 5′-antisense-thiol-
modified DsiRNA conjugates of 2 kg/mol PEG(10nM); (E) cells
treated with 5′-antisense-thiol-modified DsiRNA conjugates of 10 kg/
mol PEG (10nM); and (F) cells treated with 5′-antisense-thiol-
modified DsiRNA conjugates of 20 kg/mol PEG (10nM). Cells (1 ×
104 cells/mL) were transfected with a final concentration of 10nM in 1
mL of total well volume. Results shown are the representative images,
n = 9.
Figure 8. Immunostimulatory response of unmodified or 3′-sense PEG
conjugated DsiRNA. A representative graph showing IFIT-1 mRNA
expression in human PBMCs treated with unmodified eGFP DsiRNA
(90 nM) or 3′-10 kg/mol PEG-modified eGFP DsiRNA (90 nM).
Data were expressed as a percentage of control. All data were
normalized to the housekeeping gene β2-microglobulin (n = 3
individual PBMC isolations).
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DsiRNA could potentially shield any immune-stimulating effect
commonly observed with DsiRNA. Because the shielding effect
of 10 kDa PEG is higher than that of 2 kDa PEG and most
PEGylated therapeutics use PEGs with molecular weights larger
than 5 kDa, we used the 3′-10k conjugates for these
experiments. To assess immunogenicity, we measured the
mRNA levels of the IFN-inducible gene IFIT1. This gene is
increased upon IFN activation or directly by dsRNA receptors
including Toll-like receptor-3 (TLR-3). Therefore, its induction
is considered to be indicative of a siRNA-mediated immune
response.46 It should be noted here that the concentration
chosen for immunogenicity experiments was 90 nM, which was
the minimum concentration of unmodified DsiRNA required to
elicit a reproducible immune response in human peripheral
blood mononuclear cells collected from individual patient
donors. Our results demonstrate that unmodified DsiRNA
increased IFIT1 mRNA levels when compared with control
(untreated) cells (Figure 8). Interestingly, our PEG-modified
DsiRNA was less immunogenic when compared with the same
unmodified DsiRNA (Figure 8). Importantly, PBMCs treated
with poly(I:C) (a known immune activator) showed a
significant increase in IFIT-1 levels, confirming that the isolated
PBMCs were responsive to immune stimulation (Figure S9,
SI). The reduced immunogenicity observed with the PEG
conjugate was attributed to the shielding effect of PEG since
fluorescence microscopy results (Figures 6 and 7) showed that
there was very little difference in the level of eGFP knockdown
between the 3′-10k conjugate and the unmodified DsiRNA
(note that all of the samples were used at the same
concentration, 10 nM), suggesting that the transfection
efficiency of the two were similar. However, detailed
investigations on the immunogenicity of the conjugates should
be performed in future studies.
■ CONCLUSIONS
In this study, 3′-sense or 5′-antisense thiol-modified, blunt-
ended DsiRNAs targeting eGFP gene were conjugated with
acrylate-modified PEGs having varying molecular weights via a
physiologically stable bond. The recombinant Human Dicer
was able to efficiently release 21-mer siRNA from 2k conjugates
(both 3′-2k and 5′-2k conjugates) and 3′-10k conjugate. Cells
treated with 2 and 10 kg/mol PEG conjugated to the 3′-sense
strand of DsiRNA showed potent gene silencing activity at both
the mRNA and protein levels. PEG conjugates of 5′-antisense
strand of DsiRNA showed less gene silencing activity compared
with the 3′-sense strand DsiRNA conjugates, in accord with
Dicer cleavage profile of the 5′-conjugates. Interestingly, 10 kg/
mol PEG conjugates of the 3′-sense strand of DsiRNA were less
immunogenic when compared with the same unmodified
DsiRNA.
In summary, this study presents a new strategy for siRNA
release from polymeric delivery vehicles. Whereas PEG was
utilized in this study for conjugation to DsiRNA and proved to
reduce the immunogenicity of DsiRNA, it is also possible to
utilize varying functional polymers such as endosomal
disruptive polymers, actively targeting or fusogenic peptides
to deliver siRNA into the cells using this new release strategy.
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